Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, Cardlytics, Block, and Crocs and Encourages Investors to Contact the Firm

By: Bragar Eagel & Squire via GlobeNewswire

March 03, 2025 at 21:00 PM EST

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ESSA Pharma Inc. (NASDAQ: EPIX), Cardlytics, Inc. (NASDAQ: CDLX), Block, Inc. (NYSE: SQ), and Crocs, Inc. (NASDAQ: CROX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

ESSA Pharma Inc. (NASDAQ: EPIX)

Class Period: December 12, 2023 - October 31, 2024

Lead Plaintiff Deadline: March 25, 2025

The Complaint alleges that, throughout the Class Period, the Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants allegedly made false and/or misleading statements and/or failed to disclose that: (1) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (2) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than Defendants had led investors to believe; (3) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint; (4) accordingly, Defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.

For more information on the ESSA class action go to: https://bespc.com/cases/EPIX

Cardlytics, Inc. (NASDAQ: CDLX)

Class Period: March 14, 2024 - August 7, 2024

Lead Plaintiff Deadline: March 25, 2025

According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) increasing consumer engagement led to an increase in consumer incentives; (2) Cardlytics could not increase its billings commensurate with the increased consumer engagement; (3) as a result, there was a significant risk that its revenue growth would slow or decline; (4) the changes to Cardlytics’ Ads Decision Engine (“ADE”), which led to increased consumer engagement, led to the “underdelivery” of budgets and customers billing estimates; and (5) as a result of the foregoing, defendants’ positive statements about Cardlytics’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

For more information on the Cardlytics class action go to: https://bespc.com/cases/CDLX

Block, Inc. (NYSE: SQ)

Class Period: February 26, 2020 - April 30, 2024

Lead Plaintiff Deadline: March 18, 2025

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Block had engaged in widespread and years-long compliance lapses at Square and Cash App, including by failing to conduct basic due diligence regarding its customers’ identities or the nature of customer transactions so as to prevent the platforms from being used for illegal or illicit activities; (2) Block had effectively created a haven for widespread illegal and illicit activities on its Square and Cash App platforms by imposing minimal obligations on customers seeking to open accounts, transact, and deposit or withdraw funds; encouraging the use of bitcoin; and pressuring Block’s banking partners to forgo ordinary know your customer due diligence activities; (3) thousands of transactions on Square and Cash App were made in connection with a wide variety of illegal and illicit activities, including, , money laundering, child sexual abuse, sex trafficking, drug trafficking, terrorism financing, contract killings, and illicit payments to entities and persons subject to economic sanctions; (4) Block allowed its customers to withdraw funds even after the accounts had been flagged for potentially illegal or illicit activities; (5) Block customers could open up multiple accounts using fake identities in order to engage in illegal or illicit activities; (6) Block’s senior leadership and the Board of Directors had failed to correct identified compliance deficiencies despite numerous red flags, internal employee reports of deficiencies, and customer complaints; (7) Block’s Cash App user metrics had been artificially inflated through the use of fake accounts and the ability of criminals and other bad actors to open multiple accounts; and (8) as a result of the above, Block was subject to a material, undisclosed risk of its conduct being exposed, thereby exposing Block to reputational harm, adverse regulatory actions, the loss of business activity, and adverse impacts to Block’s operations and financial results.

For more information on the Block class action go to: https://bespc.com/cases/SQ

Crocs, Inc. (NASDAQ: CROX)

Class Period: November 3, 2022 - October, 28 2024

Lead Plaintiff Deadline: March 24, 2025

According to the lawsuit, Defendants made misrepresentations concerning the fact that the strong revenue growth exhibited by HEYDUDE, another footwear brand Crocs acquired in February 2022, was largely driven by a conscious decision on the part of Crocs management to aggressively stock its third-party wholesaler pipeline with HEYDUDE products, regardless of the level of retail demand being experienced by those wholesalers.

For more information on the Crocs class action go to: https://bespc.com/cases/CROX

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

About Us

Laser Focus World Membership

Magazine Subscription

Newsletter Subscription

The Daily Beam

Product Watch

Bio & Life Sciences Product Watch

Laser Processing Product Watch

Get Published!

Photonics Hot List

Following the Photons: A Photonics Podcast

Social Media

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, Cardlytics, Block, and Crocs and Encourages Investors to Contact the Firm

More News